ALAMEDA, Calif.-- (BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex: BTIM) today reported financial results for the first quarter ended March 31, 2010 and provided an update on recent corporate developments.

BioTime, Inc. (NYSE: BTX ) is a clinical-stage biotechnology company focused on regenerative medicine and pluripotent stem cell technologies. It was established by Dr. Michael D. West, the ...

BioTime, Inc. and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Human Embryonic Stem Cell Lines ALAMEDA, Calif., Nov 29, 2010 (BUSINESS WIRE) -- ...

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the second quarter ended June ...

Cleveland stem cell technology developer Cell Targeting has sold its assets to BioTime, which specializes in stem cells for use in regenerative medicine and blood plasma volume expanders for use ...

The primary customer for Hextend remains the U.S. armed forces. BioTime has claimed in the past that Hextend has a $750 million addressable market. Asensio & Company put out a very comprehensive ...

BioTime announced plan to spin-off AgeX Therapeutics. The separation is expected to occur during the end of September 2018. Spin-Off Research, founded by Joe Cornell, has tracked and provided ...

BioTime (BTX) delivered earnings and revenue surprises of 600.00% and 40.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

BioTime, Inc. (NYSE MKT: BTX) and BioTime’s subsidiary OncoCyte Corporation today announced the publication of a scientific report on the gene and its potential as a marker for numerous types of ...

BioTime is developing Renevia™ (formerly known as HyStem®-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications.

ALAMEDA, Calif.-- (BUSINESS WIRE)--BioTime, Inc. (OTCBB: BTIM) announced today that Walter Funk, Ph.D. has joined its management team as Vice President for Stem Cell Research. Dr. Funk will ...

BioTime's HyStem® hydrogels are proprietary biocompatible hydrogels that mimic the human extracellular matrix (ECM), a web of molecules surrounding cells that is essential to cellular function.